MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval2019/05/31STEM CELL THERAPEUTIC
MEDIPOST, announces a domestic and international clinical experience at the ISCT annual meeting2019/05/30STEM CELL THERAPEUTIC
Results from the US Clinical Trial of PNEUMOSTEM for Treating Lung Disease is Published in International Journal2019/05/13STEM CELL THERAPEUTIC
MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)2019/03/26STEM CELL THERAPEUTIC
MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture method2019/01/30STEM CELL THERAPEUTIC
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants2019/01/08STEM CELL THERAPEUTIC
MEDIPOST, signs a contract with SK Bioland for an ankle joint indication2019/01/02STEM CELL THERAPEUTIC
MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method’2018/10/24STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
